Rinvoq — Medical Mutual

Initial criteria

• Patient age > 18 years
• Patient has tried one systemic corticosteroid
• Rinvoq is prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• Patient has been established on therapy for at least 6 months
• Patient experienced a beneficial clinical response when assessed by ≥ 1 objective measure from baseline OR compared with baseline patient experienced improvement in ≥ 1 symptom such as decreased headache, scalp or jaw pain, fatigue, or improved vision

Approval duration

initial 6 months; renewal 1 year